Radiomics Nomogram Based on Multiple-Sequence Magnetic Resonance Imaging Predicts Long-Term Survival in Patients Diagnosed With Nasopharyngeal Carcinoma.
multiple-sequence MRI
nasopharyngeal carcinoma
nomogram
overall survival
prediction model
radiomics
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
01
2022
accepted:
04
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Although the tumor-node-metastasis staging system is widely used for survival analysis of nasopharyngeal carcinoma (NPC), tumor heterogeneity limits its utility. In this study, we aimed to develop and validate a radiomics model, based on multiple-sequence magnetic resonance imaging (MRI), to estimate the probability of overall survival in patients diagnosed with NPC. Multiple-sequence MRIs, including T1-weighted, T1 contrast, and T2-weighted imaging, were collected from patients diagnosed with NPC. Radiomics features were extracted from the contoured gross tumor volume of three sequences from each patient using the least absolute shrinkage and selection operator with the Cox regression model. The optimal Rad score was determined using 12 of the 851 radiomics features derived from the multiple-sequence MRI and its discrimination power was compared in the training and validation cohorts. For better prediction performance, an optimal nomogram (radiomics nomogram-MS) that incorporated the optimal Rad score and clinical risk factors was developed, and a calibration curve and a decision curve were used to further evaluate the optimized discrimination power. A total of 504 patients diagnosed with NPC were included in this study. The optimal Rad score was significantly correlated with overall survival in both the training [C-index: 0.731, 95% confidence interval (CI): 0.709-0.753] and validation cohorts (C-index: 0.807, 95% CI: 0.782-0.832). Compared with the nomogram developed with only single-sequence MRI, the radiomics nomogram-MS had a higher discrimination power in both the training (C-index: 0.827, 95% CI: 0.809-0.845) and validation cohorts (C-index: 0.836, 95% CI: 0.815-0.857). Analysis of the calibration and decision curves confirmed the effectiveness and utility of the optimal radiomics nomogram-MS. The radiomics nomogram model that incorporates multiple-sequence MRI and clinical factors may be a useful tool for the early assessment of the long-term prognosis of patients diagnosed with NPC.
Identifiants
pubmed: 35463366
doi: 10.3389/fonc.2022.852348
pmc: PMC9021720
doi:
Types de publication
Journal Article
Langues
eng
Pagination
852348Informations de copyright
Copyright © 2022 Liu, Qiu, Qin, Chen, Zhang, Huang, Yin and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2011 Dec 1;29(34):4516-25
pubmed: 22025164
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Rofo. 2017 May;189(5):413-422
pubmed: 28449168
Eur Radiol. 2021 Aug;31(8):6078-6086
pubmed: 33515086
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Magn Reson Imaging. 2012 Nov;30(9):1234-48
pubmed: 22898692
Eur J Radiol. 2021 Jul;140:109744
pubmed: 33962253
Front Oncol. 2020 Aug 11;10:1398
pubmed: 32850451
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Cancer Treat Rev. 2020 Apr;85:101995
pubmed: 32113080
EBioMedicine. 2019 Apr;42:270-280
pubmed: 30928358
Lancet Oncol. 2012 Feb;13(2):163-71
pubmed: 22154591
EBioMedicine. 2021 Aug;70:103522
pubmed: 34391094
J Cancer. 2017 Aug 3;8(13):2595-2603
pubmed: 28900497
Transl Cancer Res. 2021 Oct;10(10):4375-4386
pubmed: 35116296
Eur Radiol. 2020 Jan;30(1):537-546
pubmed: 31372781
J Magn Reson Imaging. 2021 Sep;54(3):854-865
pubmed: 33830573
Radiat Oncol. 2018 Aug 13;13(1):148
pubmed: 30103765
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066161
N Engl J Med. 2017 Aug 10;377(6):513-522
pubmed: 28792880
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Eur Radiol. 2019 Oct;29(10):5590-5599
pubmed: 30874880
J Natl Compr Canc Netw. 2018 May;16(5):479-490
pubmed: 29752322
Clin Radiol. 2018 Jan;73(1):45-59
pubmed: 28655406
Clin Cancer Res. 2019 Jan 15;25(2):584-594
pubmed: 30397175
Sci Rep. 2019 Jul 18;9(1):10412
pubmed: 31320729
Clin Cancer Res. 2017 Aug 1;23(15):4259-4269
pubmed: 28280088
Cancer Lett. 2016 Apr 28;374(1):22-30
pubmed: 26828135
Diagnostics (Basel). 2021 Aug 24;11(9):
pubmed: 34573865
Oral Oncol. 2020 Dec;111:104925
pubmed: 32721816